These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 11521253)
41. Pharmaceuticals: drug importation--2005. End of Year Issue Brief. Varma P; Seay M Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708457 [No Abstract] [Full Text] [Related]
43. FDA user fees and innovation. Somberg J Am J Ther; 2008; 15(2):97. PubMed ID: 18356626 [No Abstract] [Full Text] [Related]
44. Pros and cons of off-label promotion investigations and prosecutions. Loucks MK Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041 [No Abstract] [Full Text] [Related]
45. Drug safety on trial. Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579 [No Abstract] [Full Text] [Related]
46. Painkiller in the dock. Nature; 2005 Jul; 436(7050):459. PubMed ID: 16049447 [No Abstract] [Full Text] [Related]
47. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
48. Supplements and other changes to an approved application. Final rule. Food and Drug Administration, HHS Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041 [TBL] [Abstract][Full Text] [Related]
49. Pharmaceuticals and medical devices: FDA oversight. Chaps NA Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718 [No Abstract] [Full Text] [Related]
50. Pharmaceutical postmarket review: fact or fiction? Schanz SJ Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391 [No Abstract] [Full Text] [Related]
51. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
52. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related]
53. Drug safety: a contrarian's point of view. Cobert B Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392 [No Abstract] [Full Text] [Related]
55. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related]
57. Advertisements. FDA orders Abbott to change misleading ads for Norvir. AIDS Policy Law; 2004 Jul; 19(12):9. PubMed ID: 15282864 [No Abstract] [Full Text] [Related]
58. The new drug marketing: a consumer protection perspective. Woodward D Food Drug Law J; 1996; 51(4):637-50. PubMed ID: 11797733 [No Abstract] [Full Text] [Related]
59. FDA's regulation of prescription drug labeling: a role for implied preemption. Kendrick LC Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031 [No Abstract] [Full Text] [Related]
60. Current good manufacturing practices for PET drug products in the United States. Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]